Results from the trial demonstrated that combination treatment with Adcetris plus CHP was superior to the control arm for progression free survival (PFS)
All other key secondary endpoints were met
A recent small study indicated that Adcetris used combination with other treatments may increase lung toxicity in children and young adults.
Adcetris generated approximately $640 million in 2017
